Bioresorbable drug-eluting scaffolds for treatment of vascular disease
© 2016 Informa UK Limited. Introduction: Theoretical advantages of fully bioresorbable scaffold (BRS) stem from transient vessel support without rigid caging. Therefore, it could reduce long-term adverse events associated with the presence of foreign materials.Areas covered: This article will provid...
Saved in:
Main Authors: | Suwannasom P., Sotomi Y., Tateishi H., Tenekecioglu E., Zeng Y., Kraak R., Wykrzykowska J., De Winter R., Serruys P., Onuma Y. |
---|---|
Format: | Journal |
Published: |
2017
|
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84961205510&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/41890 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Bioresorbable drug-eluting scaffolds for treatment of vascular disease
by: Pannipa Suwannasom, et al.
Published: (2018) -
Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
by: Yohei Sotomi, et al.
Published: (2018) -
Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: From bench to clinical use
by: Yohei Sotomi, et al.
Published: (2018) -
Is quantitative coronary angiography reliable in assessing the lumen gain after treatment with the everolimus-eluting bioresorbable polylactide scaffold?
by: Sotomi Y., et al.
Published: (2017) -
Change in lumen eccentricity and asymmetry after treatment with Absorb bioresorbable vascular scaffolds in the ABSORB cohort B trial: A five-year serial optical coherence tomography imaging study
by: Suwannasom P., et al.
Published: (2017)